Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma

Triple‐hit lymphoma (THL), which is classified into high‐grade B‐cell lymphoma with rearrangements of MYC, BCL2 and BCL6, presents aggressive biological behaviour. High‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto‐HSCT) is considered to be one of the recomme...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Junnan, Zhang, Yizhuo, Ding, Sa, Yasheng, Kalbinur, Li, Yueyang, Yu, Yong, Wang, Yafei, Tian, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581337/
https://www.ncbi.nlm.nih.gov/pubmed/34698437
http://dx.doi.org/10.1111/jcmm.16999
Descripción
Sumario:Triple‐hit lymphoma (THL), which is classified into high‐grade B‐cell lymphoma with rearrangements of MYC, BCL2 and BCL6, presents aggressive biological behaviour. High‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto‐HSCT) is considered to be one of the recommended treatment options. Here, we reported 3 THL patients received carmustine, etoposide, cytarabine and cyclophosphamide (BEAC) combined with chidamide and high‐dose rituximab conditioning regimen and found that this conditioning showed good efficacy and tolerance without increase of adverse events.

Ejemplares similares